Long-term Efficacy and Safety of Lamivudine, Entecavir, and Tenofovir for Treatment of Hepatitis B Virus-Related Cirrhosis

Basit Öğe Kaydı
dc.contributor.authorKoklu, Seyfettin
dc.contributor.authorTuna, Yasar
dc.contributor.authorGulsen, Murat Taner
dc.contributor.authorDemir, Mehmet
dc.contributor.authorKoksal, Aydin Seref
dc.contributor.authorKockar, Muhammet Cem
dc.contributor.authorAygun, Cem
dc.date.accessioned2020-03-26T18:42:23Z
dc.date.available2020-03-26T18:42:23Z
dc.date.issued2013
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractBACKGROUND & AIMS: Data are limited on the efficacy and safety of tenofovir and entecavir when given for more than 1 year to patients with hepatitis B-related cirrhosis. We investigated the long-term safety and efficacy of these antiviral drugs in patients with chronic hepatitis B virus (HBV) infection, with compensated or decompensated cirrhosis, and compared results with those from lamivudine. METHODS: We performed a retrospective analysis of data from 227 adult patients with chronic HBV infection who were diagnosed with cirrhosis, beginning in 2005, at 18 centers throughout Turkey. There were 104 patients who had decompensated cirrhosis, and 197 patients were treatment naive before. Seventy-two patients received tenofovir (followed up for 21.4 +/- 9.7 mo), 77 patients received entecavir (followed up for 24.0 +/- 13.3 mo), and 74 patients received lamivudine (followed up for 36.5 +/- 24.1 mo). We collected data on patient demographics and baseline characteristics. Laboratory test results, clinical outcomes, and drug-related adverse events were compared among groups. RESULTS: Levels of HBV DNA less than 400 copies/mL were achieved in 91.5%, 92.5%, and 77% of patients receiving tenofovir, entecavir, or lamivudine, respectively. Levels of alanine aminotransferase normalized in 86.8%, 92.1%, and 71.8% of patients who received tenofovir, entecavir, and lamivudine, respectively. Child-Turcotte-Pugh scores increased among 8.5% of patients who received tenofovir, 15.6% who received entecavir, and 27.4% who received lamivudine. Frequencies of complications from cirrhosis, including hepatic encephalopathy, variceal bleeding, hepatocellular carcinoma, and mortality, were similar among groups. Lamivudine had to be changed to another drug for 32.4% of the patients. CONCLUSIONS: Tenofovir and entecavir are effective and safe for long-term use in patients with compensated or decompensated cirrhosis from HBV infection.en_US
dc.identifier.doi10.1016/j.cgh.2012.10.003en_US
dc.identifier.endpage94en_US
dc.identifier.issn1542-3565en_US
dc.identifier.issn1542-7714en_US
dc.identifier.issue1en_US
dc.identifier.pmid23063679en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage88en_US
dc.identifier.urihttps://dx.doi.org/10.1016/j.cgh.2012.10.003
dc.identifier.urihttps://hdl.handle.net/20.500.12395/29619
dc.identifier.volume11en_US
dc.identifier.wosWOS:000313112900020en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherELSEVIER SCIENCE INCen_US
dc.relation.ispartofCLINICAL GASTROENTEROLOGY AND HEPATOLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectLiver Functionen_US
dc.subjectVaricesen_US
dc.subjectAscitesen_US
dc.subjectHCC Incidenceen_US
dc.titleLong-term Efficacy and Safety of Lamivudine, Entecavir, and Tenofovir for Treatment of Hepatitis B Virus-Related Cirrhosisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu